There is increasing evidence of pathological effects of dysregulated FGF23 levels, such as induction of left ventricular hypertrophy, cardiac fibrosis, and dysfunction, and FGF23 is therefore discussed as a risk factor and biomarker for cardiovascular disease (16). The gene discussed is FGF23; the disease is left ventricular hypertrophy.